BARCELONA, Spain and TAIPEI, Feb. 25, 2026 /PRNewswire/ — TMYTEK and Metanoia announce collaboration for open ecosystem 5G FR2 gNB solutions. By combining MetanoiaBARCELONA, Spain and TAIPEI, Feb. 25, 2026 /PRNewswire/ — TMYTEK and Metanoia announce collaboration for open ecosystem 5G FR2 gNB solutions. By combining Metanoia

TMYTEK and Metanoia Announce Strategic Collaboration on 5G FR2 gNB Solutions at MWC Barcelona

2026/02/25 21:30
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

BARCELONA, Spain and TAIPEI, Feb. 25, 2026 /PRNewswire/ — TMYTEK and Metanoia announce collaboration for open ecosystem 5G FR2 gNB solutions. By combining Metanoia’s Software Defined Radio (SDR) chipset and “ALBIZIA” FR2 development platform with TMYTEK’s Antenna-in-Package (AiP) antenna array modules, the companies provide compact, high-performance FR2 gNB architectures for Fixed Wireless Access (FWA) and commercial 5G networks, simplifying system integration and shortening time-to-market for now and next-generation wireless infrastructure.

TMYTEK’s AiP modules feature embedded FPGA-based beam steering and mature APIs, streamlining gNB integration and accelerating the path from prototype to product. TMYTEK’s AiP modules complies with both O-RAN and FAPI standards for open cross-platform integration and minimized beam steering latency.

Metanoia’s SoC based FR2 SDR “ALBIZIA” gNB platform provides the core baseband processing and system architecture required for 5G FR2, while TMYTEK’s AiP modules integrate the RF front end, antenna array, and beam control into a single compact module.

TMYTEK’s AiP modules support FR2 n257 and n258 bands operating in range from 24.25 GHz to 29.5 GHz, and further coming n260 bands.

“The collaboration with Metanoia represents a practical and system-driven approach to accelerating FR2 gNB deployment,” said Su-Wei Chang, Founder and President of TMYTEK. “By tightly integrating our AiP antenna array modules with Metanoia’s gNB platform, we provide a streamlined path for customers to deploy compact, high-performance mmWave solutions with shorter development cycles.”

“We are very pleased to work with AiP market leaders like TMYTEK to expand the 5G FR2 ecosystem” said Dave Hoelscher, Global Sales VP of Metanoia Communications.

Visitors can learn more about TMYTEK’s FR2 AiP portfolio at TMYTEK Hall 5 Booth #5J93, or Metanoia meeting rooms 5L24MR, 5L26MR

About TMYTEK

TMY Technology, Inc. (TMYTEK) is a global leader in mmWave innovation, offering advanced solutions for research, education, and industry applications. Specializing in phased array antenna modules and pioneering mmWave research tools, TMYTEK serves key markets such as 5G/B5G, satellite communication, automotive, and defense. By driving breakthroughs in wireless communication and enabling next-generation technologies, TMYTEK empowers its partners to address complex challenges and seize new opportunities. With a commitment to high-quality manufacturing and customer-centric solutions, TMYTEK is shaping the future of connectivity and advancing global competitiveness. Find out more at tmytek.com.

News Contact: Grace Ho / marketing@tmytek.com

About Metanoia

Metanoia Communications Inc. is headquartered in Hsinchu Science Park, Taiwan, specializing in Software Defined Radio (SDR) SoC solutions for 5G Open RAN Radio Units and small cells. Metanoia enables partners to accelerate radio development with integrated, power-efficient silicon designed for next-generation networks.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/tmytek-and-metanoia-announce-strategic-collaboration-on-5g-fr2-gnb-solutions-at-mwc-barcelona-302696857.html

SOURCE TMYTEK

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09